中科微点-全球专利检索

  1. Login
  2. Sign Up

Search Results

7 records (took 0.018 seconds)

    Anti-CepsilonmX antibodies capable of binding to human mIgE on B lymphocytes
    1.
    发明专利
    Anti-CepsilonmX antibodies capable of binding to human mIgE on B lymphocytes 未知

    公开(公告)号：AU2014203008B2

    公开(公告)日：2016-03-31

    申请号：AU2014203008

    申请日：2014-06-03

    Applicant: ACADEMIA SINICA

    Inventor： CHANG TSEWEN ,  CHEN JIUN-BO ,  WU PHEIDIAS ,  HUNG ALFUR F

    IPC: C07K16/28 ,  A61K38/10 ,  A61K39/395 ,  A61P37/00

    Abstract: ANTI-CEmX ANTIBODIES CAPABLE OF BINDING TO HUMAN mIgE ON B LYMPHOCYTES Abstract The invention pertains to the generation and utility of antibodies that can bind effectively to CEmX domain on membrane-bound IgE (mlgE) expressed on the surface of human B lymphocytes. The CEmX domain of 52 amino acid residues, located between the CH4 domain and the C-terminal membrane-anchor peptide on human membrane-bound epsilon chain, had been suggested as an antigenic site for immunological targeting of B cells expressing mlgE. Previous reported monoclonal antibodies, including a20, which bind to RADWPGPP peptide at the C-terminal of CEmX, have now been found to bind poorly to mlgE on human B cells. We have discovered that only monoclonal antibodies specific for certain segments, such as GLAGGSAQSQRAPDRVL and HSGQQQGLPRAAGGSVPHPR, of CEmX can bind effectively to mlgE on human B cells and hence have the utility for targeting those B cells for the treatment of diseases mediated by IgE.

    Anti-CepsilonmX antibodies capable of binding to human mIgE on B lymphocytes
    3.
    发明专利
    Anti-CepsilonmX antibodies capable of binding to human mIgE on B lymphocytes 未知

    公开(公告)号：AU2010217100B2

    公开(公告)日：2014-03-27

    申请号：AU2010217100

    申请日：2010-02-25

    Applicant: ACADEMIA SINICA

    Inventor： CHANG TSEWEN ,  CHEN JIUN-BO ,  WU PHEIDIAS C ,  HUNG ALFUR F

    IPC: C07K16/28 ,  A61K38/10 ,  A61K39/395 ,  A61P37/00

    Abstract: The invention pertains to the generation and utility of antibodies that can bind effectively to C&egr;mX domain on membrane-bound IgE (mIgE) expressed on the surface of human B lymphocytes. The C&egr;mX domain of 52 amino acid residues, located between the CH4 domain and the C-terminal membrane-anchor peptide on human membrane-bound epsilon chain, had been suggested as an antigenic site for immunological targeting of B cells expressing mlgE. Previous reported monoclonal antibodies, including a20, which bind to RADWPGPP peptide at the C-terminal of C&egr;mX, have now been found to bind poorly to mlgE on human B cells. We have discovered that only monoclonal antibodies specific for certain segments, such as GLAGGSAQSQRAPDRVL and HSGQQQGLPRAAGGSVPHPR, of C&egr;mX can bind effectively to mlgE on human B cells and hence have the utility for targeting those B cells for the treatment of diseases mediated by IgE.

    ANTI-C mX ANTIBODIES CAPABLE OF BINDING TO HUMAN mIgE ON B LYMPHOCYTES
    7.
    发明公开
    ANTI-C mX ANTIBODIES CAPABLE OF BINDING TO HUMAN mIgE ON B LYMPHOCYTES 有权
    AN ICH E ON ON ON ON ON ER ER ER ER ER ER ER ER ER ER ER ER

    公开(公告)号：EP2401300A4

    公开(公告)日：2013-01-23

    申请号：EP10745796

    申请日：2010-02-25

    Applicant: ACADEMIA SINICA

    Inventor： CHANG TSEWEN ,  CHEN JIUN-BO ,  WU PHEIDIAS C ,  HUNG ALFUR F

    IPC: C07K16/28 ,  A61K38/10 ,  A61K39/395 ,  A61P37/00 ,  C07K16/42

    CPC classification number: C07K16/2803 ,  A61K39/39566 ,  C07K16/4291 ,  C07K2317/24 ,  C07K2317/30 ,  C07K2317/34 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/73 ,  C07K2317/732 ,  Y10S424/805 ,  Y10S424/81 ,  Y10S530/862 ,  Y10S530/868

    Abstract: The invention pertains to the generation and utility of antibodies that can bind effectively to CepsilonmX domain on membrane-bound IgE (mIgE) expressed on the surface of human B lymphocytes. The CepsilonmX domain of 52 amino acid residues, located between the CH4 domain and the C-terminal membrane-anchor peptide on human membrane-bound epsilon chain, had been suggested as an antigenic site for immunological targeting of B cells expressing mIgE. Previous reported monoclonal antibodies, including a20, which bind to RADWPGPP (SEQ ID NO:1) peptide at the C-terminal of CepsilonmX, have now been found to bind poorly to mIgE on human B cells. We have discovered that only monoclonal antibodies specific for certain segments, such as GLAGGSAQSQRAPDRVL (SEQ ID NO:2) and HSGQQQGLPRAAGGSVPHPR (SEQ ID NO:3), of CepsilonmX can bind effectively to mIgE on human B cells and hence have the utility for targeting those B cells for the treatment of diseases mediated by IgE.

    Abstract translation: 本发明涉及可在人B淋巴细胞表面表达的膜结合IgE（mIgE）上有效结合CepsilonmX结构域的抗体的产生和应用。 已经提出位于人膜结合的ε链上的CH4结构域和C末端膜锚定肽之间的52个氨基酸残基的Cepsilonm结构域作为用于免疫靶向表达mIgE的B细胞的抗原位点。 现在已经发现，先前报道的包含与CepsilonmX C末端的RADWPGPP（SEQ ID NO：1）肽结合的α20的单克隆抗体已经发现与人B细胞上的mIgE不良结合。 我们已经发现，只有对某些片段特异性的单克隆抗体，如GLEGGSAQSQRAPDRVL（SEQ ID NO：2）和HSGQQQGLPRAAGGSVPHPR（SEQ ID NO：3）），可以有效地结合人B细胞上的mIgE，因此具有靶向 用于治疗IgE介导的疾病的B细胞。

Patent Agency Ranking